Brief: Sana Biotechnology Announces Increased Focus On Type 1 Diabetes And B-Cell Mediated Autoimmune Diseases With The Potential To Deliver Clinical Proof Of Concept Data Across Multiple Studies In 2024 And 2025

Sana Biotechnology

04/11/2024 21:34

Nov 4 (Reuters) - Sana Biotechnology Inc  SANA.O :
    * SANA BIOTECHNOLOGY ANNOUNCES INCREASED FOCUS ON TYPE 1
DIABETES
AND B-CELL MEDIATED AUTOIMMUNE DISEASES WITH THE POTENTIAL TO
DELIVER CLINICAL PROOF OF CONCEPT DATA ACROSS MULTIPLE STUDIES
IN 2024 AND 2025
    * SANA BIOTECHNOLOGY INC - TO PRIORITIZE SC291 IN B-CELL
MEDIATED
AUTOIMMUNE DISEASES
    * SANA BIOTECHNOLOGY INC - SUSPENDS DEVELOPMENT OF SC291 IN
ONCOLOGY AND SC379
    * SANA BIOTECHNOLOGY INC - 2024 OPERATING CASH BURN MAY
EXCEED
$200 MILLION
    * SANA BIOTECHNOLOGY INC - HALTS ENROLLMENT IN SC291
ONCOLOGY
TRIAL

Source text:  ID:nGNX4Nt7GS 
Further company coverage:  SANA.O 

 ((Reuters.Briefs@thomsonreuters.com;))